Latest & greatest articles for Renin Angiotensin System

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Renin Angiotensin System or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Renin Angiotensin System and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Renin Angiotensin System

21. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. Full Text available with Trip Pro

Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. To determine whether the prescription of co-trimoxazole with an angiotensin converting enzyme inhibitor or angiotensin receptor blocker is associated with sudden death.Population based nested case-control study.Ontario, Canada, from 1 April 1994 to 1 January 2012.Ontario residents aged 66 years or older treated with an angiotensin converting enzyme inhibitor or angiotensin (...) prolongation) was also associated with an increased risk of sudden death (adjusted odds ratio 1.29, 1.03 to 1.62), but no such risk was observed with nitrofurantoin or norfloxacin.In older patients receiving angiotensin converting enzyme inhibitors or angiotensin receptor blockers, co-trimoxazole is associated with an increased risk of sudden death. Unrecognized severe hyperkalemia may underlie this finding. When appropriate, alternative antibiotics should be considered in such patients.© Fralick et al

2014 BMJ

22. Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function?new warnings

Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function?new warnings Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function—new warnings - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Combination use of medicines from different classes of renin-angiotensin system (...) blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function—new warnings New warnings due to risk of hyperkalaemia, hypotension, and impaired renal function have been agreed following an EU-wide review. Published 11 December 2014 From: Therapeutic area: , , Contents Article date: June 2014 The renin-angiotensin hormone system (RAS) controls blood pressure and the volume of fluids in the body. Medicines that have an inhibitory action on the RAS (RAS blocking agents) are used

2014 MHRA Drug Safety Update

23. The End of Dual Therapy with Renin-Angiotensin-Aldosterone System Blockade? (Abstract)

The End of Dual Therapy with Renin-Angiotensin-Aldosterone System Blockade? 24206456 2013 11 22 2018 12 02 1533-4406 369 20 2013 Nov 14 The New England journal of medicine N. Engl. J. Med. The end of dual therapy with renin-angiotensin-aldosterone system blockade? 1960-2 10.1056/NEJMe1312286 de Zeeuw Dick D From the Department of Clinical Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. eng Editorial Comment 2013 11 09 United States N Engl (...) J Med 0255562 0028-4793 0 Angiotensin II Type 1 Receptor Blockers 0 Angiotensin-Converting Enzyme Inhibitors E7199S1YWR Lisinopril JMS50MPO89 Losartan AIM IM N Engl J Med. 2013 Nov 14;369(20):1892-903 24206457 Angiotensin II Type 1 Receptor Blockers therapeutic use Angiotensin-Converting Enzyme Inhibitors therapeutic use Diabetic Nephropathies drug therapy Female Humans Lisinopril therapeutic use Losartan therapeutic use Male 2013 11 12 6 0 2013 11 12 6 0 2013 12 16 6 0 ppublish 24206456 10.1056

2013 NEJM

24. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial (Abstract)

Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial Blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers has been shown to lessen the rate of decrease in glomerular filtration rate in patients with diabetic nephropathy.A multicenter open-label randomized controlled trial to compare the efficacy of combining the angiotensin-converting enzyme inhibitor (...) lisinopril and the angiotensin II receptor blocker irbesartan with that of each drug in monotherapy (at both high and equipotent doses) in slowing the progression of type 2 diabetic nephropathy.133 patients with type 2 diabetic nephropathy (age, 66 ± 8 years; 76% men) from 17 centers in Spain.Patients were randomly assigned (1:1:2) to lisinopril (n = 35), irbesartan (n = 28), or the combination of both (n = 70).The primary composite outcome was a >50% increase in baseline serum creatinine level, end

2013 EvidenceUpdates Controlled trial quality: predicted high

25. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials

Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH CRD summary The authors concluded that compared with monotherapy, combination blockade of the renin-angiotensin system had some (...) beneficial effects, but it did not reduce mortality and significantly compromised safety. Despite some limitations in the review, there were a lot of trials, and larger trials tended to find similar effects, which suggests that the authors' conclusions are likely to be reliable. Authors' objectives To compare the long-term efficacy and safety of individual versus combined blockade of the renin-angiotensin system, for patients with various disorders. Searching PubMed, EMBASE, and Cochrane Central Register

2013 DARE.

26. Effects of renin-angiotensin system blockades on cardiovascular outcomes in patients with diabetes mellitus: a systematic review and meta-analysis

Effects of renin-angiotensin system blockades on cardiovascular outcomes in patients with diabetes mellitus: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

27. Cohort study: Renin-angiotensin system blockers increase risk of angio-oedema

Cohort study: Renin-angiotensin system blockers increase risk of angio-oedema Renin-angiotensin system blockers increase risk of angio-oedema | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Renin-angiotensin system blockers increase risk of angio-oedema Article Text Aetiology Cohort study Renin-angiotensin system blockers increase risk of angio-oedema Massimo Volpe , Giuliano Tocci Statistics from Altmetric.com Commentary on: Toh S

2013 Evidence-Based Medicine

28. Cohort study: Lack of definitive evidence for the use of renin-angiotensin system antagonists for heart failure with preserved ejection fraction

Cohort study: Lack of definitive evidence for the use of renin-angiotensin system antagonists for heart failure with preserved ejection fraction Lack of definitive evidence for the use of renin-angiotensin system antagonists for heart failure with preserved ejection fraction | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Lack of definitive evidence for the use of renin-angiotensin system antagonists for heart failure with preserved

2013 Evidence-Based Medicine

29. The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy

The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

30. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis

The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

31. An economic evaluation of a laboratory monitoring program for renin-angiotensin system agents

An economic evaluation of a laboratory monitoring program for renin-angiotensin system agents An economic evaluation of a laboratory monitoring program for renin-angiotensin system agents An economic evaluation of a laboratory monitoring program for renin-angiotensin system agents Smith DH, Raebel MA, Chan KA, Johnson ES, Petrik AF, Weiss JR, Yang X, Feldstein A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of extended laboratory monitoring during renin-angiotensin system (RAS) therapy to prevent adverse events, such as hyperkalaemia and acute renal failure. The authors concluded that increased laboratory monitoring could be cost-effective for patients starting RAS therapy

2011 NHS Economic Evaluation Database.

32. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies (Abstract)

Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies cardiovascular risk factors are associated with dementia and cognitive decline. We investigated the effects of renin-angiotensin system blockade on cognitive function in patients aged 55 years and older with established atherosclerotic cardiovascular disease or diabetes with end-organ damage in two clinical trials.in the main study (...) of the renin-angiotensin system had no clear effects on cognitive outcomes. Although patients with the lowest systolic blood pressure had the greatest preservation of cognitive function, meta-regression analyses did not show any benefits of blood-pressure lowering on cognition over several years of treatment.

2011 EvidenceUpdates Controlled trial quality: predicted high

33. Dual renin-angiotensin system blockade for patients with prosthesis-patient mismatch (Abstract)

Dual renin-angiotensin system blockade for patients with prosthesis-patient mismatch Patients with prosthesis-patient mismatch (PPM) continue to show some degrees of left ventricular hypertrophy after aortic valve replacement for aortic stenosis. The renin-angiotensin system plays a major role in promoting and sustaining hypertrophy. In a controlled, randomized study, we tested the hypothesis that the combination of angiotensin-converting enzyme inhibitors (ACEi) plus angiotensin II receptor

2011 EvidenceUpdates Controlled trial quality: uncertain

34. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis

The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

35. The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials

The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

36. Clinical consequences of withholding versus administering renin-angiotensin-aldosterone system antagonists in the preoperative period

Clinical consequences of withholding versus administering renin-angiotensin-aldosterone system antagonists in the preoperative period Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

37. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease Kunz R, Friedrich C, Wolbers M, Mann J F CRD summary This review assessed (...) details Kunz R, Friedrich C, Wolbers M, Mann J F. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Annals of Internal Medicine 2008; 148(1): 30-48 PubMedID Other publications of related interest This additional published commentary may also be of interest. Kohn O. Review: combination therapy with renin angiotensin inhibitors reduces proteinuria more than single drugs alone in renal disease. Evid Based Med

2008 DARE.

38. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis

Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

39. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis

Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis Balamuthusamy S, Srinivasan L, Verma M, Adigopula S, Jalandara N, Hathiwala S, Smith E CRD (...) summary The authors concluded that among patients with chronic kidney disease from any cause, renin angiotensin system blockade reduced myocardial infarctions, heart failure and overall cardiovascular adverse events compared with placebo. The conclusions may need to be interpreted cautiously due to the small number of studies included in the main analyses, unexplained heterogeneity and inconsistent findings across different clinical outcomes. Authors' objectives To determine the effects of renin

2008 DARE.

40. Renin-angiotensin system and cardiovascular risk. (Abstract)

Renin-angiotensin system and cardiovascular risk. The renin-angiotensin system is a major regulatory system of cardiovascular and renal function. Basic research has revealed exciting new aspects, which could lead to novel or modified therapeutic approaches. Renin-angiotensin system blockade exerts potent antiatherosclerotic effects, which are mediated by their antihypertensive, anti-inflammatory, antiproliferative, and oxidative stress lowering properties. Inhibitors of the system-ie (...) , angiotensin converting enzyme inhibitors and angiotensin receptor blockers, are now first-line treatments for hypertensive target organ damage and progressive renal disease. Their effects are greater than expected by their ability to lower blood pressure alone. Angiotensin receptor blockers reduce the frequency of atrial fibrillation and stroke. Renin-angiotensin system blockade delays or avoids the onset of type 2 diabetes and prevents cardiovascular and renal events in diabetic patients. Thus, blockade

2007 Lancet